Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
‘A Testimonial to Not Giving Up’: Otsuka’s New DTx Offers Hope for Behavioral Health Industry
Behavioral Health Business November 1, 2024
Almost 10% of Americans will experience a depressive illness in their life.
Despite depression’s prevalence, the burgeoning digital therapeutics (DTx) industry had, until recently, not made a dedicated attempt to treat the illness.
Now, pharmaceutical giant Otsuka’s (OTCMKTS:OTSKY) company, Otsuka Precision Health, has created the first FDA-approved digital therapeutic designed to treat depression alongside an antidepressant medication.
Otsuka Precision Health focuses specifically on bringing prescription digital therapeutics and other technologies to market.
The U.S. Food and Drug Administration (FDA) approved Otsuka Precision Health’s Rejoyn product earlier this year for patients aged 22 and older diagnosed with major depressive disorder (MDD). The digital treatment is delivered through an app via a six-week program and is prescribed by a clinician.
...Today's Sponsors
Today's Sponsor